Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
Intrinsic Value
Fisher & Paykel Healthcare Corp. Ltd. engages in the designing, manufacturing and marketing of medical device products and systems for use in respiratory care, acute care and the treatment of obstruct... [ Read More ]
The intrinsic value of one FPH stock under the Base Case scenario is 16.97 NZD. Compared to the current market price of 26.78 NZD, Fisher & Paykel Healthcare Corporation Ltd is Overvalued by 37%.
Valuation Backtest
Fisher & Paykel Healthcare Corporation Ltd
Run backtest to discover the historical profit from buying and selling FPH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Fisher & Paykel Healthcare Corporation Ltd
Current Assets | 729.2m |
Cash & Short-Term Investments | 70.5m |
Receivables | 261.9m |
Other Current Assets | 396.8m |
Non-Current Assets | 1.7B |
PP&E | 1.4B |
Intangibles | 85.5m |
Other Non-Current Assets | 155.7m |
Current Liabilities | 286.8m |
Accounts Payable | 212.7m |
Other Current Liabilities | 74.1m |
Non-Current Liabilities | 351.2m |
Long-Term Debt | 299.6m |
Other Non-Current Liabilities | 51.6m |
Earnings Waterfall
Fisher & Paykel Healthcare Corporation Ltd
Revenue
|
1.7B
NZD
|
Cost of Revenue
|
-682.9m
NZD
|
Gross Profit
|
1B
NZD
|
Operating Expenses
|
-653.2m
NZD
|
Operating Income
|
358.1m
NZD
|
Other Expenses
|
-96.4m
NZD
|
Net Income
|
261.7m
NZD
|
Free Cash Flow Analysis
Fisher & Paykel Healthcare Corporation Ltd
What is Free Cash Flow?
FPH Profitability Score
Profitability Due Diligence
Fisher & Paykel Healthcare Corporation Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Fisher & Paykel Healthcare Corporation Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
FPH Solvency Score
Solvency Due Diligence
Fisher & Paykel Healthcare Corporation Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Fisher & Paykel Healthcare Corporation Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FPH Price Targets Summary
Fisher & Paykel Healthcare Corporation Ltd
According to Wall Street analysts, the average 1-year price target for FPH is 24.84 NZD with a low forecast of 21.72 NZD and a high forecast of 29.93 NZD.
Shareholder Return
FPH Price
Fisher & Paykel Healthcare Corporation Ltd
Average Annual Return | 17.92% |
Standard Deviation of Annual Returns | 38.85% |
Max Drawdown | -50% |
Market Capitalization | 15.5B NZD |
Shares Outstanding | 583 964 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fisher & Paykel Healthcare Corp. Ltd. engages in the designing, manufacturing and marketing of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The firm offers its products across hospital and homecare settings. The Company’s hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include the Company’s continuous positive airway pressure (CPAP) therapy masks, as well as flow generators, interfaces, and data management technologies. The firm operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India, Germany, Austria, Italy, Turkey, China, Hong Kong, Taiwan, Malaysia, Singapore and Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one FPH stock under the Base Case scenario is 16.97 NZD.
Compared to the current market price of 26.78 NZD, Fisher & Paykel Healthcare Corporation Ltd is Overvalued by 37%.